Navigation Links
Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2012 Global Healthcare Conference in New York
Date:5/30/2012

SAN FRANCISCO, May 30, 2012 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the Jefferies 2012 Global Healthcare Conference at The Grand Hyatt New York on Tuesday, June 5, 2012 at 11:30 a.m. Eastern Time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website http://www.nektar.com. This webcast will be available for replay until July 5, 2012.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which is being evaluated in Phase 3 clinical studies as a once- daily, oral tablet for the treatment of opioid-induced constipation. This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic in development to treat chronic pain, has completed Phase 1 development and is being prepared for a Phase 2 study.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In oncology, etirinotecan pegol (NKTR-102) is being evaluated in a Phase 3 clinical study for the treatment of metastatic breast cancer and in Phase 2 studies for the treatment of ovarian and colorectal cancers.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including Affymax's OMONTYS® for anemia, UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Additional development-stage products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a long-acting PEGylated rFVIII program, which is in Phase 1 clinical development.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.Nektar Investor Inquiries:Jennifer Ruddock/Nektar Therapeutics

(415) 482-5585Susan Noonan/SA Noonan Communications, LLC

(212) 966-3650Nektar Media Inquiries: Karen Bergman/BCC Partners

(650) 575-1509


'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2020)... ... August 27, 2020 , ... Bleep LLC, maker of ... sleep apnea patient, is the company’s new spokesperson. , “In my line of work, ... when I found the Bleep DreamPort it was a Bleeping no brainer for me,” ...
(Date:8/27/2020)... ... , ... Bridge To A Cure Foundation announces the appointment of Henry Friedman, ... who serves on the Board of Directors at The Preston Robert Tisch Brain Tumor ... Internationally recognized, Dr. Friedman is a widely published author of more than 500 peer ...
(Date:8/26/2020)... ... August 26, 2020 , ... ScripHessco has announced ... The infographic breaks down ways that chiropractors can help heal sports injuries and ... ScripHessco “Athletes have an unusual amount of pressure and stress on their bodies, ...
Breaking Medicine Technology:
(Date:8/29/2020)... ... August 29, 2020 , ... When professor and author Randy ... ease than most people would. Rather than become melancholic, however, he put together a ... achieving one’s dreams. Randy Pausch took a negative situation and turned it into something ...
(Date:8/28/2020)... (PRWEB) , ... August 28, 2020 , ... ... assist system designed to help treat patients with respiratory conditions, including COVID-19, while ... of helium and oxygen, but it captures exhaled gas and scrubs it free ...
(Date:8/28/2020)... (PRWEB) , ... August 28, 2020 , ... ... The Nourished Group set out to continue helping the specialty-diet community connect ... discover new gluten-free products, get coupons, enter giveaways, chat with brands & watch ...
(Date:8/28/2020)... ... , ... Ziegler, a specialty investment bank, is pleased to ... a tech-enabled behavioral health and well-being solutions provider. , Synchronous Health, a ... (AI) to increase access and quality of behavioral health services, and Adventist Health, ...
(Date:8/27/2020)... N.Y. (PRWEB) , ... August 27, 2020 , ... ... DePinto, has joined the Walk-in Dermatology team in its Greenvale, New York location. ... Island Nail and Skin Care Institute. She is certified in chemical peels, microdermabrasion, ...
Breaking Medicine News(10 mins):